Collaboration Agreement for Value Based Healthcare Project 5.2 Immuno-Oncology Related Adverse Events: Feasiblity of Risk Prediction in Clinical Practice.

Analysis of risk factors for immune-related adverse events induced by immune checkpoint inhibitor treatment in cancer: A comprehensive systematic review

B Jayathilaka, F Mian, J Cockwill, F Franchini, G Au-Yeung, M IJzerman

2025-03-01

Background: Immune-related adverse events (irAE) pose challenges to the use of immune checkpoint inhibitors (ICI). While risk fact..

Cancer and treatment specific incidence rates of immune-related adverse events induced by immune checkpoint inhibitors: a systematic review: Epidemiology

B Jayathilaka, F Mian, F Franchini, G Au-Yeung, M IJzerman

2025-01-31

Background: Immune-related adverse events (irAE) induced by immune checkpoint inhibitors (ICI) are a treatment-limiting barrier. T..

572P Estimating rates of immune-related adverse events in an Australian state-wide hospital population

B Jayathilaka, F He, M Ijzerman, G Au-Yeung, F Franchini

2024-12-01

Estimating rates of immune-related adverse events in an Australian state-wide hospital population

Bishma Jayathilaka, Fan He, Maarten IJzerman, George Au-Yeung, Fanny Franchini

2024-11-01

Correction to: Cancer and treatment specific incidence rates of immune-related adverse events induced by immune checkpoint inhibitors: a systematic review

B Jayathilaka, F Mian, F Franchini, G Au-Yeung, M IJzerman

2024-01-01

In this article values in the sentence “Mean event rate for ICI monotherapy was 29.7% (27.7–33.2%), 45.7% (29.6–61.7%) for ICI com..